A Critical Deposition Blocked
One of the most significant Medicare Advantage fraud cases has encountered a procedural hurdle, as the Department of Justice (DOJ) is being denied access to a key witness. According to a DOJ letter to a presiding judge, Elevance Health is blocking the deposition of Peter Haytaian, an outgoing executive who formerly oversaw the health insurer's Medicare Advantage plans. The letter further reveals that Elevance announced Haytaian's departure immediately after the DOJ first requested his testimony. This dispute highlights the high stakes of the lawsuit, originally filed in 2020, and adds to the growing scrutiny of Elevance's private Medicare plans, which generated over $40 billion in revenue last year.
Background of the Medicare Advantage Fraud Case
The Allegations
The DOJ alleges that Elevance Health (formerly Anthem) engaged in systematic fraud by submitting false diagnoses to Medicare Advantage to inflate payments from the federal government. Medicare Advantage plans, also known as Part C, are private insurance alternatives to traditional Medicare, and they are paid based on the health risk scores of enrolled beneficiaries. The government argues that Elevance knowingly submitted inaccurate risk adjustment data, leading to overpayments of billions of dollars. The case is part of a broader wave of litigation targeting Medicare Advantage insurers for similar practices.
Lawsuit History and Escalation
The DOJ intervened in a whistleblower lawsuit in 2020, taking over the case from private relators. Since then, the litigation has moved through discovery, with both sides exchanging evidence and witness lists. The case has already resulted in significant document productions and depositions of lower-level employees, but the DOJ now seeks testimony from a top executive who oversaw the very plans under scrutiny.
The Deposition Dispute: DOJ vs. Elevance
Who Is Peter Haytaian?
Peter Haytaian served as a senior executive at Elevance Health, responsible for the company's Medicare Advantage business during the period in question. His role included oversight of risk adjustment coding and the submission of data to the Centers for Medicare & Medicaid Services (CMS). The DOJ believes Haytaian possesses firsthand knowledge of the company's policies and practices regarding diagnosis coding. His testimony could be critical to proving whether the fraud was intentional or systemic.
The Timing of His Departure
The DOJ letter notes that Elevance announced Haytaian's departure on the same day or shortly after the government requested his deposition. The company stated that he would leave his post by the end of 2023, but the timing raised suspicions among DOJ attorneys. They argue that this sudden exit appears intended to avoid or delay his deposition, potentially depriving the government of vital evidence. Elevance disputes this characterization, stating that Haytaian's retirement had been planned independently.
Legal Arguments Over Access
The DOJ has asked the court to compel Elevance to produce Haytaian for a deposition. The company, in turn, has resisted, claiming that the executive's departure and ongoing transition make him unavailable for the near term. The DOJ counters that Elevance continues to employ Haytaian in a consulting role and that he remains under the company's control. The letter warns that without his testimony, the government's ability to build its case may be severely hampered.
Financial and Legal Stakes
The lawsuit could result in billions of dollars in damages, including treble damages under the False Claims Act, as well as potential exclusion from federal health programs. Elevance's Medicare Advantage business is a major revenue driver, and any adverse ruling could impact not only the company but also the broader industry. The case is being closely watched by other insurers who face similar allegations.
Implications for Medicare Advantage Oversight
This deposition dispute underscores the challenges regulators face in investigating complex fraud schemes within Medicare Advantage. Insurers have a financial incentive to maximize risk scores, and the line between legitimate chart review and fraudulent upcoding remains debated. The DOJ's aggressive pursuit of high-level executives signals a shift toward holding individuals accountable, not just corporations. The outcome of this dispute may also influence how courts handle executive privileges and deposition logistics in fraud cases.
As the legal battle continues, both sides are preparing for a potentially lengthy trial. The DOJ's access to Peter Haytaian could prove pivotal, and the judge's decision on the deposition request will likely set the stage for the next phase of discovery. With billions of taxpayer dollars at stake, the resolution of this case will have far-reaching consequences for Medicare Advantage and the health insurance industry.